{
    "clinical_study": {
        "@rank": "28595", 
        "arm_group": [
            {
                "arm_group_label": "risperidone", 
                "arm_group_type": "Active Comparator", 
                "description": "low dosage of  antipsychotic drug"
            }, 
            {
                "arm_group_label": "olanzapine", 
                "arm_group_type": "Active Comparator", 
                "description": "low doseage of antipsychotic"
            }, 
            {
                "arm_group_label": "quetiapine", 
                "arm_group_type": "Active Comparator", 
                "description": "low doseage of antipsychotic"
            }, 
            {
                "arm_group_label": "aripiprazole", 
                "arm_group_type": "Active Comparator", 
                "description": "low doseage of antipsychotic"
            }
        ], 
        "brief_summary": {
            "textblock": "This study assess the safety and effects of atypical antipsychotics in subjects with\n      psychosis syndrome and psychosis risk syndrome."
        }, 
        "brief_title": "Antipsychotic to Treat Psychosis Syndrome", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Psychotic Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators investigated whether administration of atypical antipsychotics could\n      alleviate prodromal symptoms and be well tolerated by subjects with psychosis syndrome and\n      psychosis risk syndrome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  were help-seeking young individuals in outpatients service\n\n          -  aged 16-30 years\n\n          -  fitted one of the following Criteria: Psychosis-risk Syndromes (COPS-SIPS) or\n             Psychotic Syndrome (POPS-SIPS) or DSM-IV diagnosis of schizophreniform disorder\n\n        Exclusion Criteria:\n\n          -  a previous diagnosis of any psychotic disorder or bipolar disorders according to the\n             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;\n\n          -  symptoms fully accounted for by an Axis 1 disorder or sequelae of drug/alcohol use;\n\n          -  neurological disorders or organic disorders affecting the central nervous system,\n             substance-related disorders or mental retardation as defined by the DSM-IV criteria;\n\n          -  history treatment of antipsychotic or antidepression, mood stabilizers or\n             electroconvulsive therapy;\n\n          -  diagnosed as having a serious and unstable medical condition."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137616", 
            "org_study_id": "201002003"
        }, 
        "intervention": [
            {
                "arm_group_label": "risperidone", 
                "description": "Risperdal tablets", 
                "intervention_name": "risperidone", 
                "intervention_type": "Drug", 
                "other_name": "Risperidol"
            }, 
            {
                "arm_group_label": "olanzapine", 
                "description": "olanzapine tablets", 
                "intervention_name": "olanzapine", 
                "intervention_type": "Drug", 
                "other_name": "olanzapine tablets"
            }, 
            {
                "arm_group_label": "quetiapine", 
                "description": "quetiapine tablets", 
                "intervention_name": "Quetiapine", 
                "intervention_type": "Drug", 
                "other_name": "quetiapine tablets"
            }, 
            {
                "arm_group_label": "aripiprazole", 
                "description": "Aripiprazole tablets", 
                "intervention_name": "Aripiprazole", 
                "intervention_type": "Drug", 
                "other_name": "Aripiprazole tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "Risperidone", 
                "Quetiapine", 
                "Olanzapine", 
                "Aripiprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "psychosis", 
            "syndrome", 
            "risk", 
            "antipsychotic"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "fengcsu@yahoo.com.cn", 
                "last_name": "Xiaofeng Guo, dr", 
                "phone": "073185554052", 
                "phone_ext": "073185554052"
            }, 
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410011"
                }, 
                "name": "the Second Xiangya Hospital"
            }, 
            "investigator": {
                "last_name": "xiaofeng Guo, dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study", 
        "overall_contact": {
            "email": "fengcsu@yahoo.com.cn", 
            "last_name": "xiaofeng Guo, Dr.", 
            "phone": "073185554052", 
            "phone_ext": "073185554052"
        }, 
        "overall_official": {
            "affiliation": "the second xiangya hospitcal", 
            "last_name": "xiaofeng Guo, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes of PANSS total scores from baseline to 18 months", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137616"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central South University", 
            "investigator_full_name": "xiaofeng Guo", 
            "investigator_title": "prof.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Social function was assessed by the Global Assessment of Functioning (GAF) every three month", 
                "measure": "Social function", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Adverse Events were assessed at baseline and every month after treatments", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Central South University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Central South University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}